Radiotherapy is highly involved in the management of prostate cancer. Its features and potential applications experienced a radical evolution over last decades, as they are associated to the continuous evolution of available technology and current oncological innovations. Some application of radiotherapy like brachytherapy have been recently enriched by innovative features and multidisciplinary dedications. In this report we aim to put some questions regarding the following issues regarding multiple aspects of modern application of radiation oncology: the current application of radiation oncology; the modern role of stereotactic body radiotherapy (SBRT) for both the management of primary lesions and for lymph-nodal recurrence; the management of the oligometastatic presentations; the role of brachytherapy; the aid played by the application of the organ at risk spacer (spacer OAR), fiducial markers, electromagnetic tracking systems and on-line Magnetic Resonance guided radiotherapy (MRgRT), and the role of the new opportunity represented by radiomic analysis.
MichalskiJMBaeKRoachM, et al. Long-term toxicity following 3D conformal radiation therapy for prostate cancer from the RTOG 9406 phase I/II dose escalation study. Int J Radiat Oncol Biol Phys2010; 76(1): 14–22.
DangAKupelianPACaoM, et al. Image-guided radiotherapy for prostate cancer. Transl Androl Urol2018; 7(3): 308–320.
4.
MottetNvan den BerghRCNBriersE, et al. EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer-2020 update. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol2021; 79(2): 243–262.
5.
HuntAHansenVNOelfkeU, et al. Adaptive radiotherapy enabled by MRI guidance. Clin Oncol (R Coll Radiol)2018; 30(11): 711–719.
6.
HoffmanKEVoongKRLevyLB, et al. Randomized trial of hypofractionated, dose-escalated, intensity-modulated radiation therapy (IMRT) versus conventionally fractionated IMRT for localized prostate cancer. J Clin Oncol2018; 36(29): 2943–2949.
7.
WolffRFRyderSBossiA, et al. A systematic review of randomised controlled trials of radiotherapy for localised prostate cancer. Eur J Cancer2015; 51(16): 2345–2367.
8.
MichalskiJMMoughanJPurdyJ, et al. Effect of standard vs dose-escalated radiation therapy for patients with intermediate-risk prostate cancer: the NRG oncology RTOG 0126 randomized clinical trial. JAMA Oncol2018; 4(6): e180039.
9.
PotoskyALDavisWWHoffmanRM, et al. Five-year outcomes after prostatectomy or radiotherapy for prostate cancer: the prostate cancer outcomes study. J Natl Cancer Inst2004; 96(18): 1358–1367.
10.
NguyenPLD’AmicoAVLeeAK, et al. Patient selection, cancer control, and complications after salvage local therapy for postradiation prostate-specific antigen failure: a systematic review of the literature. Cancer2007; 110(7): 1417–1428.
11.
BollaMVan TienhovenGWardeP, et al. External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study. Lancet Oncol2010; 11(11): 1066–1073.
12.
MerrickGSButlerWMWallnerKE, et al. Permanent interstitial brachytherapy in younger patients with clinically organ-confined prostate cancer. Urology2004; 64(4): 754–759.
13.
MorisLCumberbatchMGVan den BroeckT, et al. Benefits and risks of primary treatments for high-risk localized and locally advanced prostate cancer: an international multidisciplinary systematic review. Eur Urol2020; 77(5): 614–627.
14.
ThompsonImJrTangenCMParadeloJ, et al. Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial. JAMA2006; 296(19): 2329–2335.
15.
ParkerCCJamesNDBrawleyCD, et al. Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial. Lancet2018; 392(10162): 2353–2366.
RoyceTJEfstathiouJA.Proton therapy for prostate cancer: a review of the rationale, evidence, and current state. Urol Oncol2019; 37(9): 628–636.
18.
PanHYJiangJHoffmanKE, et al. Comparative toxicities and cost of intensity-modulated radiotherapy, proton radiation, and stereotactic body radiotherapy among younger men with prostate cancer. J Clin Oncol2018; 36(18): 1823–1830.
19.
MorganSCHoffmanKLoblawDA, et al. Hypofractionated radiation therapy for localized prostate cancer: executive summary of an ASTRO, ASCO and AUA evidence-based guideline. J Urol2019; 201(3): 528–534.
20.
SundahlNDe MeerleerGVilleirsG, et al. Combining high dose external beam radiotherapy with a simultaneous integrated boost to the dominant intraprostatic lesion: analysis of genito-urinary and rectal toxicity. Radiother Oncol2016; 119(3): 398–404.
21.
von EybenFEKiljunenTKangasmakiA, et al. Radiotherapy boost for the dominant intraprostatic cancer lesion-a systematic review and meta-analysis. Clin Genitourin Cancer2016; 14(3): 189–197.
22.
BollaMHenryAMasonM, et al. The role of radiotherapy in localised and locally advanced prostate cancer. Asian J Urol2019; 6(2): 153–161.
23.
MonninkhofEMvan LoonJWLvan VulpenM, et al. Standard whole prostate gland radiotherapy with and without lesion boost in prostate cancer: toxicity in the FLAME randomized controlled trial. Radiother Oncol2018; 127(1): 74–80.
24.
FeutrenTHerreraFG.Prostate irradiation with focal dose escalation to the intraprostatic dominant nodule: a systematic review. Prostate Int2018; 6(3): 75–87.
25.
CelliniNMorgantiAGMattiucciGC, et al. Analysis of intraprostatic failures in patients treated with hormonal therapy and radiotherapy: implications for conformal therapy planning. Int J Radiat Oncol Biol Phys2002; 53(3): 595–599.
26.
BuwengeMAlittoARCillaS, et al. Simultaneous integrated radiotherapy boost to the dominant intraprostatic lesion: final results of a phase I/II trial. Anticancer Res2020; 40(11): 6499–6503.
27.
IppolitoEMantiniGMorgantiAG, et al. Intensity-modulated radiotherapy with simultaneous integrated boost to dominant intraprostatic lesion: preliminary report on toxicity. Am J Clin Oncol2012; 35(2): 158–162.
28.
KerkmeijerLGWGroenVHPosFJ, et al. Focal boost to the intraprostatic tumor in external beam radiotherapy for patients with localized prostate cancer: results from the FLAME randomized phase III trial. J Clin Oncol2021; 39(7): 787–796.
29.
McDonaldAMDobelbowerMCYangES, et al. Prostate stereotactic body radiation therapy with a focal simultaneous integrated boost: acute toxicity and dosimetry results from a prospective trial. Adv Radiat Oncol2019; 4(1): 90–95.
30.
PathmanathanAUvan AsNJKerkmeijerLGW, et al. Magnetic resonance imaging-guided adaptive radiation therapy: a “game changer” for prostate treatment?Int J Radiat Oncol Biol Phys2018; 100(2): 361–373.
31.
HenkeLEContrerasJAGreenOL, et al. Magnetic resonance image-guided radiotherapy (MRIgRT): a 4.5-year clinical experience. Clin Oncol (R Coll Radiol)2018; 30(11): 720–727.
32.
SwansonGPRiggsMHermansM. Pathologic findings at radical prostatectomy: risk factors for failure and death. Urol Oncol2007; 25(2): 110–114.
33.
RogowskiPRoachM3rdSchmidt-HegemannNS, et al. Radiotherapy of oligometastatic prostate cancer: a systematic review. Radiat Oncol2021; 16(1): 50.
34.
Jereczek-FossaBAFanettiGFodorC, et al. Salvage stereotactic body radiotherapy for isolated lymph node recurrent prostate cancer: single institution series of 94 consecutive patients and 124 lymph nodes. Clin Genitourin Cancer2017; 15(4): e623–e632.
35.
IngrossoGTrippaFMaranzanoE, et al. Stereotactic body radiotherapy in oligometastatic prostate cancer patients with isolated lymph nodes involvement: a two-institution experience. World J Urol2017; 35(1): 45–49.
36.
PontiELanciaAOstP, et al. Exploring all avenues for radiotherapy in oligorecurrent prostate cancer disease limited to lymph nodes: a systematic review of the role of stereotactic body radiotherapy. Eur Urol Focus2017; 3(6): 538–544.
37.
CalaisJCzerninJCaoM, et al. 68)Ga-PSMA-11 PET/CT mapping of prostate cancer biochemical recurrence after radical prostatectomy in 270 patients with a PSA level of less than 1.0 ng/mL: impact on salvage radiotherapy planning. J Nucl Med2018; 59(2): 230–237.
38.
PinkawaMAebersoldDMBöhmerD, et al. Radiotherapy in nodal oligorecurrent prostate cancer. Strahlenther Onkol2021; 197: 575–580.
39.
D’AngelilloRMFrancoliniGIngrossoG, et al. Consensus statements on ablative radiotherapy for oligometastatic prostate cancer: a position paper of Italian Association of Radiotherapy and Clinical Oncology (AIRO). Crit Rev Oncol Hematol2019; 138: 24–28.
40.
PhillipsRShiWYDeekM, et al. Outcomes of observation vs stereotactic ablative radiation for oligometastatic prostate cancer: the ORIOLE phase 2 randomized clinical trial. JAMA Oncol2020; 6(5): 650–659.
TosoianJJGorinMARossAE, et al. Oligometastatic prostate cancer: definitions, clinical outcomes, and treatment considerations. Nat Rev Urol2017; 14(1): 15–25.
43.
NiibeYHayakawaK. Oligometastases and oligo-recurrence: the new era of cancer therapy. Jpn J Clin Oncol2010; 40(2): 107–111.
44.
PatelPHPalmaDMcDonaldF, et al. The dandelion dilemma revisited for oligoprogression: treat the whole lawn or weed selectively?Clin Oncol (R Coll Radiol)2019; 31(12): 824–833.
45.
SalujaRCheungPZukotynskiK, et al. Disease volume and distribution as drivers of treatment decisions in metastatic prostate cancer: from chemohormonal therapy to stereotactic ablative radiotherapy of oligometastases. Urol Oncol2016; 34(5): 225–232.
46.
LievensYGuckenbergerMGomezD, et al. Defining oligometastatic disease from a radiation oncology perspective: an ESTRO-ASTRO consensus document. Radiother Oncol2020; 148: 157–166.
47.
OstPReyndersDDecaesteckerK, et al. Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: a prospective, randomized, multicenter phase II trial. J Clin Oncol2018; 36(5): 446–453.
48.
LehrerEJSinghRWangM, et al. Safety and survival rates associated with ablative stereotactic radiotherapy for patients with oligometastatic cancer: a systematic review and meta-analysis. JAMA Oncol2021; 7(1): 92–106.
49.
WallisCJDSaskinRChooR, et al. Surgery versus radiotherapy for clinically-localized prostate cancer: a systematic review and meta-analysis. Eur Urol2016; 70(1): 21–30.
50.
WangZNiYChenJ, et al. The efficacy and safety of radical prostatectomy and radiotherapy in high-risk prostate cancer: a systematic review and meta-analysis. World J Surg Oncol2020; 18(1): 42.
51.
ZietmanALDeSilvioMLSlaterJD, et al. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. JAMA2005; 294(10): 1233–1239.
52.
KubanDATuckerSLDongL, et al. Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys2008; 70(1): 67–74.
53.
AlittoARTagliaferriLLancellottaV, et al. BIT-ART: multicentric comparison of HDR-brachytherapy, intensity-modulated radiotherapy and tomotherapy for advanced radiotherapy in prostate cancer. In Vivo2020; 34(3): 1297–1305.
54.
SkowronekJ. Low-dose-rate or high-dose-rate brachytherapy in treatment of prostate cancer - between options. J Contemp Brachytherapy2013; 5(1): 33–41.
55.
CossetJMHaie-MederC. Brachytherapy for prostate cancer: high dose rate or low-dose rate?Cancer Radiother2005; 9(8): 610–619.
56.
KovácsGPötterRLochT, et al. GEC/ESTRO-EAU recommendations on temporary brachytherapy using stepping sources for localised prostate cancer. Radiother Oncol2005; 74(2): 137–148.
HoskinP. High dose rate brachytherapy for prostate cancer. Cancer Radiother2008; 12(6-7): 512–514.
59.
KovácsGMüllerKSororT, et al. Results of multiparametric transrectal ultrasound-based focal high-dose-rate dose escalation combined with supplementary external beam irradiation in intermediate- and high-risk localized prostate cancer patients. Brachytherapy2017; 16(2): 277–281.
60.
HoskinPJRojasAMOstlerPJ, et al. Randomised trial of external-beam radiotherapy alone or with high-dose-rate brachytherapy for prostate cancer: mature 12-year results. Radiother Oncol2021; 154: 214–219.
61.
HoskinPJColomboAHenryA, et al. GEC/ESTRO recommendations on high dose rate afterloading brachytherapy for localised prostate cancer: an update. Radiother Oncol2013; 107(3): 325–332.
62.
TagliaferriLVavassoriALancellottaV, et al. Can brachytherapy be properly considered in the clinical practice? Trilogy project: the vision of the AIRO (Italian Association of Radiotherapy and Clinical Oncology) interventional radiotherapy study group. J Contemp Brchytherapy2020; 12(1): 84–90.
63.
HanKMilosevicMFylesA, et al. Trends in the utilization of brachytherapy in cervical cancer in the United States. Int J Radiat Oncol Biol Phys2013; 87(1): 111–119.
64.
AutorinoRVicenziLTagliaferriL, et al. A national survey of AIRO (Italian Association of Radiation Oncology) brachytherapy (Interventional Radiotherapy) study group. J Contemp Brchytherapy2018; 10(3): 254–259.
65.
TagliaferriLKovácsGAristeiC, et al. Current state of interventional radiotherapy (brachytherapy) education in Italy: results of the INTERACTS survey. J Contemp Brchytherapy2019; 11(1): 48–53.
66.
VargasCMartinezAKestinLL, et al. Dose-volume analysis of predictors for chronic rectal toxicity after treatment of prostate cancer with adaptive image-guided radiotherapy. Int J Radiat Oncol Biol Phys2005; 62(5): 1297–1308.
67.
LeikerAJDesaiNBFolkertMR. Rectal radiation dose-reduction techniques in prostate cancer: a focus on the rectal spacer. Future Oncol2018; 14(26): 2773–2788.
68.
BeydounNBucciJAChinYS, et al. First report of transperineal polyethylene glycol hydrogel spacer use to curtail rectal radiation dose after permanent iodine-125 prostate brachytherapy. Brachytherapy2013; 12(4): 368–374.
69.
SchörghoferADrerupMKunitT, et al. Rectum-spacer related acute toxicity - endoscopy results of 403 prostate cancer patients after implantation of gel or balloon spacers. Radiat Oncol2019; 14(1): 47.
70.
ChaoYSMacDougallDde NanassyA. Hydrogel spacers for patients with prostate cancer: a review of clinical effectiveness and cost-effectiveness. Ottawa, ON: CADTH Rapid Response Reports, 2019.
71.
TaggarASCharasTCohenGN, et al. Placement of an absorbable rectal hydrogel spacer in patients undergoing low-dose-rate brachytherapy with palladium-103. Brachytherapy2018; 17(2): 251–258.
72.
StromTJWilderRBFernandezDC, et al. A dosimetric study of polyethylene glycol hydrogel in 200 prostate cancer patients treated with high-dose rate brachytherapy±intensity modulated radiation therapy. Radiother Oncol2014; 111(1): 126–131.
73.
KahnJDahmanBMcLaughlinC, et al. Rectal spacing, prostate coverage, and periprocedural outcomes after hydrogel spacer injection during low-dose-rate brachytherapy implantation. Brachytherapy2020; 19(2): 228–233.
74.
YehJLehrichBTranC, et al. Polyethylene glycol hydrogel rectal spacer implantation in patients with prostate cancer undergoing combination high-dose-rate brachytherapy and external beam radiotherapy. Brachytherapy2016; 15(3): 283–287.
75.
HamstraDAMariadosNSylvesterJ, et al. Continued benefit to rectal separation for prostate radiation therapy: final results of a phase III trial. Int J Radiat Oncol Biol Phys2017; 97(5): 976–985.
76.
MillerLEEfstathiouJABhattacharyyaSK, et al. Association of the placement of a perirectal hydrogel spacer with the clinical outcomes of men receiving radiotherapy for prostate cancer: a systematic review and meta-analysis. JAMA Netw Open2020; 3(6): e208221.
77.
StanleySGriffithsSSydesMR, et al. Accuracy and reproducibility of conformal radiotherapy using data from a randomised controlled trial of conformal radiotherapy in prostate cancer (MRC RT01, ISRCTN47772397). Clin Oncol (R Coll Radiol)2008; 20(8): 582–590.
78.
ZelefskyMJYamadaYFuksZ, et al. Long-term results of conformal radiotherapy for prostate cancer: impact of dose escalation on biochemical tumor control and distant metastases-free survival outcomes. Int J Radiat Oncol Biol Phys2008; 71(4): 1028–1033.
79.
GhaffariHNavaserMMofidB, et al. Fiducial markers in prostate cancer image-guided radiotherapy. Med J Islam Repub Iran2019; 33: 15.
80.
O’NeillAGMOsmanSOJainS, et al. Observed high incidence of prostatic calculi with the potential to act as natural fiducials for prostate image guided radiotherapy. Tech Innov Patient Support Radiat Oncol9: 35–40.
81.
Lim JoonDSmithDTaceyM, et al. A phantom study to contrast and compare polymer and gold fiducial markers in radiotherapy simulation imaging. Sci Rep2021; 11(1): 8931.
82.
OsmanSOSRussellEKingRB, et al. Fiducial markers visibility and artefacts in prostate cancer radiotherapy multi-modality imaging. Radiat Oncol2019; 14(1): 237.
83.
KanedaTOhashiTHanadaT, et al. Comparison of prostate verification with implanted gold markers in tissue surrounding the prostate and pelvic bony anatomy for external beam radiation therapy following low-dose-rate brachytherapy: a prospective clinical trial. J Radiat Res2020; 61(5): 784–790.
84.
BrownAPainTPrestonR. Patient perceptions and preferences about prostate fiducial markers and ultrasound motion monitoring procedures in radiation therapy treatment. J Med Radiat Sci2021; 68(1): 37–43.
85.
RajendranRRPlastarasJPMickR, et al. Daily isocenter correction with electromagnetic-based localization improves target coverage and rectal sparing during prostate radiotherapy. Int J Radiat Oncol Biol Phys2010; 76(4): 1092–1099.
86.
KeallPJColvillEO’BrienR, et al. Electromagnetic-guided MLC tracking radiation therapy for prostate cancer patients: prospective clinical trial results. Int J Radiat Oncol Biol Phys2018; 101(2): 387–395.
87.
D’AgostinoGRMancosuPDi BrinaL, et al. Stereotactic body radiation therapy for intermediate-risk prostate cancer with VMAT and real-time electromagnetic tracking: a phase II study. Am J Clin Oncol2020; 43(9): 628–635.
88.
CorradiniSAlongiFAndratschkeN, et al. MR-guidance in clinical reality: current treatment challenges and future perspectives. Radiat Oncol2019; 14(1): 92.
89.
ToccoBRKishanAUMaTM, et al. MR-guided radiotherapy for prostate cancer. Front Oncol2020; 10: 616291.
90.
WinkelDBolGHKroonPS, et al. Adaptive radiotherapy: the Elekta unity MR-linac concept. Clin Transl Radiat Oncol2019; 18: 54–59.
91.
KlüterS. Technical design and concept of a 0.35 T MR-linac. Clin Transl Radiat Oncol2019; 18: 98–101.
92.
TetarSUBruynzeelAMELagerwaardFJ, et al. Clinical implementation of magnetic resonance imaging guided adaptive radiotherapy for localized prostate cancer. Phys Imaging Radiat Oncol2019; 9: 69–76.
93.
DunlopAMitchellATreeA, et al. Daily adaptive radiotherapy for patients with prostate cancer using a high field MR-linac: initial clinical experiences and assessment of delivered doses compared to a C-arm linac. Clin Transl Radiat Oncol2020; 23: 35–42.
94.
BruynzeelAMETetarSUOeiSS, et al. A prospective single-arm phase 2 study of stereotactic magnetic resonance guided adaptive radiation therapy for prostate cancer: early toxicity results. Int J Radiat Oncol Biol Phys2019; 105(5): 1086–1094.
95.
TetarSUBruynzeelAMEOeiSS, et al. Magnetic resonance-guided stereotactic radiotherapy for localized prostate cancer: final results on patient-reported outcomes of a prospective phase 2 study. Eur Urol Oncol2021; 4: 628–634.
96.
AlongiFRigoMFigliaV, et al. 1.5 T MR-guided and daily adapted SBRT for prostate cancer: feasibility, preliminary clinical tolerability, quality of life and patient-reported outcomes during treatment. Radiat Oncol2020; 15(1): 69.
97.
MunozFFioricaFCaravattaL, et al. Outcomes and toxicities of re-irradiation for prostate cancer: a systematic review on behalf of the re-irradiation working group of the Italian Association of Radiotherapy and Clinical Oncology (AIRO). Cancer Treat Rev2021; 95: 102176.
98.
MaTMLambJMCasadoM, et al. Magnetic resonance imaging-guided stereotactic body radiotherapy for prostate cancer (mirage): a phase III randomized trial. BMC Cancer2021; 21(1): 538.
99.
AertsHJVelazquezERLeijenaarRT, et al. Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach. Nat Commun2014; 5: 4006.
LambinPRios-VelazquezELeijenaarR, et al. Radiomics: extracting more information from medical images using advanced feature analysis. Eur J Cancer2012; 48(4): 441–446.
102.
ChaddadAKucharczykMJCheddadA, et al. Magnetic resonance imaging based radiomic models of prostate cancer: a narrative review. Cancers2021; 13(3): 552.
103.
ThenaultRGasmiAKheneZE, et al. Radiogenomics in prostate cancer evaluation. Curr Opin Urol2021; 31(4): 424–429.
104.
BodalalZTrebeschiSBeets-TanR. Radiomics: a critical step towards integrated healthcare. Insights Imaging2018; 9(6): 911–914.
105.
ZwanenburgAVallièresMAbdalahMA, et al. The image biomarker standardization initiative: standardized quantitative radiomics for high-throughput image-based phenotyping. Radiology2020; 295(2): 328–338.
106.
DinapoliNAlittoARVallatiM, et al. Moddicom: a complete and easily accessible library for prognostic evaluations relying on image features. Annu Int Conf IEEE Eng Med Biol Soc2015; 2015: 771–774.
